Ascension® Post- Approval Study; PyroCarbon Metacarpophalangeal Total Joint Prosthesis

Post-Approval Study Protocol; Ascension® MCP Finger Implant; PyroCarbon Metacarpophalangeal Total Joint Prosthesis

This study is a non-randomized, consecutive enrollment, one-year post-approval study of patients who are treated with the Ascension® MCP.

Inclusion Criteria:

• Indications consistent with the FDA approved Indications For Use: Index, long, ring, or small finger metacarpophalangeal (MCP) joints that exhibit symptoms of pain, limited motion, or inadequate bony alignment (i.e., subluxation/dislocation) secondary to articular destruction or degenerative disease related to rheumatoid arthritis, systemic lupus erythematosus, osteoarthritis, or post-traumatic arthritis where soft tissue reconstruction can provide adequate stabilization
• Willing to participate in the study
• Signed an Informed Consent Form
• The means and ability to return for all required study visits
• Are not transient

Exclusion Criteria:

Patients who have any of the following contraindications will be excluded from the study:

• Inadequate bone stock at the implantation site
• Active infection in the MCP joint
• Nonfunctioning and irreparable MCP musculotendinous system
• Physical interference with or by other prostheses during implantation or use
• Procedures requiring modification of the prosthesis
• Skin, bone, circulatory and/or neurological deficiency at the implantation site